Serum circulating microRNAs (c-miRNAs) are serving as useful biomarkers for cancer diagnosis. Here, we describe the development of a one-step branched rolling circle amplification (BRCA) method to measure serum c-miRNAs levels for early diagnosis of breast cancer. Four c-miRNAs, c-miRNA16 (c-miR-16), c-miRNA21 (c-miR-21), c-miRNA155 (c-miR-155), and c-miRNA195 (c-miR-195) were isolated from the serum of 49 breast cancer patients (stages I-IV) and 19 healthy controls, and analyzed using one-step BRCA. The serum levels of c-miR16, c-miR21, c-miR155, and c-miR195 were higher (P < 0.0001) in stage I breast cancer patients than healthy controls. These levels were also higher in several breast cancer molecular subtypes (HER-2 overexpression, Luminal A, Luminal B, and triple negative breast cancer) than in healthy control subjects. The diagnostic accuracy of c-miR16, c-miR21, c-miR155, and c-miR195 for early diagnosis of breast cancer was confirmed by receiver operating characteristic (ROC) curve assay. These results show that the BRCA method can be used to measure serum c-miRNAs levels, and that this method has high accuracy, sensitivity, and specificity. Moreover, both BRCA approach and quantitative real-time PCR (qRT-PCR) method show that the serum levels of c-miR16, c-miR21, c-miR155, and c-miR195 could be used as biomarkers to improve the early diagnosis of breast cancer, and distinguish different breast cancer molecular subtypes.
enormous potential for using as specific and non-invasive cancer biomarkers. 8, 9 In breast cancer patients, the levels of serum cmiRNA16 (c-miR-16) are significantly higher compared with healthy controls. 10, 11 Serum c-miRNA21 (c-miR-21) is one of the most upregulated c-miRNAs in breast cancer patients, indicating that it may serve as an important biomarker for breast cancer detection and progression. 12, 13 The expression of serum c-miRNA155 (c-miR155) is also increased in breast cancer patients compared with healthy controls. [14] [15] [16] In addition, the expression of c-miRNA195 (c-miR-195) is increased in breast cancer patients, but not in other cancers, indicating that it might be used as a breast cancer specific biomarker. 17, 18 However, to our knowledge, no previous studies have evaluated the diagnostic performance of the above four c-miRNAs in breast cancer early-stage detection.
Analytical methods of c-miRNAs have been hindered by measurement-associated inconveniency. 19 Some conventional techniques have been used for c-miRNA detection, such as northern blotting, microarrays, and quantitative real-time PCR (qRT-PCR). [20] [21] [22] However, these methods have low sensitivity, low selectivity, and labor-intensive steps, which limit their practical application. With the purpose of improving the sensitivity, specificity, and simplicity of c-miRNA analysis, many novel techniques have been developed. Among them, rolling circle amplification (RCA) is a simple and efficient isothermal enzymatic process that uses unique DNA or RNA polymerases to generate long single-stranded DNA (ssDNA) or RNA (ssRNA) with tens to hundreds of tandem repeats by continuously adding nucleotides (nt) to a primer of the circular template. [23] [24] [25] Unlike qRT-PCR, which not only needs two-step reactions (reverse transcription and polymerase chain reaction) but also requires a thermal cycler and thermostable DNA polymerases, RCA can be produced at an isothermal temperature from room temperature to 37°C by one-step reaction. 26 In addition, branched RCA (BRCA) is an exponential nucleic acid amplification method, where the products of RCA can be used as the template for further amplification by the addition of second and third primers. 27, 28 Moreover, in principle, in one form or the other, BRCA has been used to detect miRNAs, including c-miRNAs in serum. [29] [30] [31] T A B L E Here, we have developed, for the first time, a simple and specific BRCA method for a rapid and convenient detection of c-miR16, c-miR21, c-miR155, and c-miR195 levels in human serum specimens.
The BRCA products are long double-stranded DNAs (dsDNAs) that can be easily detected by EvaGreen dye, which is non-fluorescent by itself, but exhibits a great fluorescence enhancement upon binding to dsDNA. Furthermore, we used the BRCA method to determine the diagnostic performance of the four c-miRNAs to distinguish breast cancer patients with different histological tumor grades and molecular subtypes from healthy controls. 32, 33 Meanwhile, we also used the conventional qRT-PCR method as a secondary independent assay to verify that the four c-miRNAs could serve as biomarkers. 
| MATERIALS AND METHODS

| Reagents and consumables
| Human serum specimens
The human blood specimens of breast cancer patients and healthy were collected at the time of diagnosis, before surgery. As shown in 
| Isolation of serum circulating microRNAs
Human serums were obtained from freshly drawn blood, which were collected by standard phlebotomy in vacuum blood tubes without clot activator, kept at 4°C for 2 h to clot, and then rotate at 300 g for 5 min at 4°C. The serum was transferred into RNase-free tubes, and stored at −80°C. Circulating microRNAs were extracted from serum using the miRCURY ™ RNA Isolation Kit-Biofluids (EXIQON, Woburn, MA, USA) according to the manufacturer's protocol as shown in Doc. S1.
| Analysis of serum circulating miRNAs using
BRCA approach
The main goal of this study was to use the BRCA method to detect serum levels of c-miRNAs that could be used for early-stage diagnosis in breast cancer patients. The study consisted of two parts: The first part was the isolation of serum circulating microRNAs, and the second part was the analysis of c-miR16 (5′-UAGCAGCACGUAAAUAUUGGCG-3′), c-miR21 (5′-UAGCUUAUCAGACUGAUGUUGA-3′), c-miR155 (5′-UUAAUGCUAAUCGUGAUAGGGGU-3′), and c-miR195 (5′-UAGCAG-CACAGAAAUAUUGGC-3′) serum levels by BRCA (Figure 1 ).
The c-miRNAs intended for detection are isothermally amplified using BRCA,the DNA circular probes (miR-16 probe: The biosynthesis of DNA circular probe is shown in Figure S1 .
The circular template serving as the padlock probe DNA, which was designed to be complementary to the both ends of the ligation tem- 
| Statistical analyses
Before statistical comparisons, the specimens were divided into multiple comparison groups including health controls, different histological tumor grades, and different molecular subtypes. C-miR-16, c-miR-21, c-miR-155, and c-miR-195 expression profiles were compared using F test, Student's t test, and multiple comparison groups. Bonferroni-corrected P < 0.05 was considered statistically significant and Bonferroni-corrected P < 0.01 was considered statistically extremely significant. [34] [35] [36] Receiver operating characteristic (ROC) assay was carried out for determining the diagnostic performance of c-miR-16, c-miR-21, cmiR-155, and c-miR-195 expression in patients with breast cancer from healthy controls. Sensitivity against (1-specificity) was plotted at each cutoff threshold, and the area under the curve (AUC) values that reflect the probability of correctly identifying breast cancer patients from healthy controls were calculated. This process was repeated 1000 times, and resulting mean values (95% confidence interval) 37 for sensitivity and specificity were calculated. 
| RESULTS
| Optimization of detection system
We optimized a series of experiments to achieve the optimal detection conditions, such as the reaction temperature and the reaction time of BRCA. Firstly, as shown in Figure S2A , we optimized the Table S1 . 
| Quantitative real-time PCR assay
To validate BRCA approach for the detection of c-miRNAs in human serum, we used the conventional quantitative real-time PCR (qRT-PCR) as a secondary independent assay in which the levels of cmiRNA concentrations are verified. C-miRNAs were quantified by a commercial qRT-PCR kit (Doc. S1). The relative fluorescence units (RFU) and the threshold cycle (C t ) value were obtained on the 7500
Real-time PCR system (Applied Biosystems™, Bedford, OH, USA) and analyzed by 7500 Sequence Detection System software version
The fold change of c-miRNA expression in breast cancer serum specimens compared with healthy controls was calculated based on the C t value using the fold change = 2 −ΔΔCt method, where ΔΔC t = (C t miRNAs) breast cancer specimens -(C t miRNAs) healthy controls . As shown in In conclusion, it is the first study that demonstrates that the BRCA assay can be used to measure the serum levels of c-miRNAs 
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